www.fdanews.com/articles/84690-qlt-s-prostate-drug-shown-to-be-ineffective-in-trial
QLT'S PROSTATE DRUG SHOWN TO BE INEFFECTIVE IN TRIAL
February 20, 2006
QLT has reported that a Phase II clinical trial of lemuteporfin-injectable in patients with benign prostatic hyperplasia (BPH) did not meet the study's primary efficacy objective at three months.
While the decrease in the American Urological Association-symptom score was consistent with that seen after other minimally invasive therapies there was no significant difference between treatment and sham-control groups, the company said.